3 Matching Annotations
- Jun 2020
-
media-exp1.licdn.com media-exp1.licdn.com
-
Status of R on the Clinical Research market
- In general bioscience and academia, S ---> R has built over years its position of one of the industry standards
- In clinical research, however, SAS reigns par excellence
- Pharmaceutical companies, CROs and even FDA do use R “internally”.But they resist (or hesitate) to use it in submissions (to FDA)
- Clinical Programmer or Biostatistician ≝ SAS Programmer. Period
-
- Apr 2020
-
www.linkedin.com www.linkedin.comLinkedIn2
-
Pharma, which is one of the biggest, richest, most rewarding and promising industries in the world. Especially now, when the pharmaceutical industry, including the FDA, allows R to be used the domain occupied in 110% by SAS.
Pharma industry is one of the most rewarding industries, especially now
-
CR is one of the most controlled industries in this world. It's insanely conservative in both used statistical methods and programming. Once a program is written and validated, it may be used for decades. There are SAS macros written in 1980 working still by today without any change. That's because of brilliant backward compatibility of the SAS macro-language. New features DO NOT cause the old mechanisms to be REMOVED. It's here FOREVER+1 day.
Clinical Research is highly conservative, making SAS macros applicable for decades. Unfortunately, that's not the same case with R
-